RELMADA THERAPEUTICS, INC. (RLMD)
2025-06-30 | ||||
|---|---|---|---|---|
| Research and development | 2,819,377 | |||
| General and administrative | 7,401,929 | |||
| Total operating expenses | 10,221,306 | |||
| Loss from operations | -10,221,306 | |||
| Unrealized (loss) gain on short-term investments | -13,797 | |||
| Realized (loss) gain on short-term investments | 47,203 | |||
| Interest/investment income, net | 321,458 | |||
| Total other income | 354,864 | |||
| Net loss | -9,866,442 | |||
| Loss per common share basic (in dollars per share) | -0.3 | |||
| Loss per common share diluted (in dollars per share) | -0.3 | |||
| Weighted average number of common shares outstanding basic (in shares) | 33,191,622 | |||
| Weighted average number of common shares outstanding diluted (in shares) | 33,191,622 | |||